MENU
Aim higher

SPARKLE

Selection and development of a therapeutic antibody against drug-resistant Klebsiella pneumoniae

The consortium will develop and perform the preclinical validation of an innovative therapeutic strategy against antibiotic-resistant Klebsiella pneumoniae (ARKP) infections. Klebsiella pneumoniae (KP) is a common hospital-acquired pathogen for which, due to resistance, treatment options are very limited. The therapy is based on a therapeutic monoclonal antibody (mAb) that specifically targets ARKP. Upon completion of the project, the mAb product will be ready for further clinical development.
Ranking: 
2
Cut-off: 
7
Start date: 
01-11-2017
Project Duration: 
36months
Project costs: 
2 999 280.00€
Technological Area: 
Pharmaceutical Products / Drugs
Market Area: 
Therapeutic